

APPENDIX 4: BASELINE PARTICIPANT CHARACTERISTICS

Author, year	DAPT duration, mo	Age, yr, mean (SD)	No. (%) of participants				
			Male	Diabetes	Current smoking	Prior MI	History of heart failure
Nakamura 2017 (NIPPON) ^{*1}	6 mo	67.4 (9.6)	1304 (78.8)	619 (37.4)	960 (58.0)	201 (12.2)	NR
	18 mo	67.2 (9.9)	1312 (79.4)	635 (38.4)	997 (60.3)	195 (11.8)	
Helft 2016 (OPTIDUAL) ²	12 mo	64.2 (11.5)	547 (79.3)	222 (32.2)	399 (57.8)	122 (17.7)	8 (1.2)
	48 mo	64.1 (10.8)	568 (81.7)	213 (30.6)	425 (61.2)	119 (17.1)	4 (0.6)
Gilard 2015 (ITALIC) ³	6 mo	61.7 (10.9)	737 (81.0)	331 (36.3)	464 (50.9)	142 (15.6)	NR
	24 mo	61.5 (11.1)	721 (79.3)	344 (37.8)	480 (52.7)	134 (14.7)	
Mauri 2014 (DAPT) ⁴	12 mo	61.2 (10.3)	4318 (74.6)	1654 (28.7)	1560 (27.4)	1204 (21.1)	251 (4.4)
	30 mo	61.4 (10.3)	4405 (75.1)	1737 (29.8)	1582 (27.4)	1252 (21.7)	273 (4.7)
Lee 2014 (DES-LATE) ⁵	12 mo	62.3 (10.1)	1749 (69.6)	709 (28.2)	722 (28.7)	92 (3.7)	NR
	24 mo	62.5 (10.0)	1749 (69.1)	709 (28.0)	693 (27.4)	103 (4.1)	
Collet 2014 (ARCTIC-INT) ⁶	12 mo	64.0 (11.9)	503 (81.0)	222 (36.0)	152 (24.4)	186 (29.8)	23 (3.7)
	18–30 mo	64.0 (11.9)	508 (80.0)	198 (31.0)	147 (23.1)	197 (31.0)	20 (3.1)
Valgimigli 2012 (PRODIGY) ⁷	6 mo	67.9 (11.0)	747 (76.0)	233 (23.7)	247 (25.1)	258 (26.2)	NR
	24 mo	67.8 (11.0)	764 (77.4)	244 (24.7)	222 (22.5)	270 (27.3)	

Note: DAPT = dual anti-platelet therapy, MI = myocardial infarction, mo = months, NR = not reported, SD = standard deviation, yr = year
*Characteristics data for patients who did not experience an event in the first 6 months of DAPT.
†Assumed to be SD

Appendix 4, as supplied by the authors. Appendix to: Elliott J, Kelly SE, Bai Z, et al. Extended dual antiplatelet therapy following percutaneous coronary intervention in clinically important patient subgroups: a systematic review and meta-analysis. *CMAJ Open* 2023. doi:10.9778/cmajo.2021-0119. Copyright © 2023 The Author(s) or their employer(s). To receive this resource in an accessible format, please contact us at cmaijgroup@cmaj.ca.